Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04415645 · ClinicalTrials.gov registry record · Phase 1
Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects
A Phase 1 study, sponsored by Vivozon.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04415645: Completed Phase 1 study, sponsored by Vivozon.
NCT04415645 is a Phase 1 study that has completed, run by Vivozon. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04415645, a Phase 1 study, has completed, sponsored by Vivozon.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is an open-label, single-dose, absorption, metabolism, excretion, and mass balance study following a single IV infusion of \[14C\]-VVZ-149 in healthy adult male subjects. Whole blood, plasma, urine, and fecal samples will be analyzed for at least 72 hours following the start of infusion to measure total radioactivity and plasma drug concentrations.
Primary Outcome
Sum of the percent of the total radioactivity recovered in urine and feces relative to the administered radioactivity dose
Interventions
- DRUG [14C]-VVZ-149
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-02-24 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 1 |
What the finished NCT04415645 record still lists
NCT04415645 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which [14C]-VVZ-149 is the first listed.
NCT04415645 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04415645 about?
NCT04415645 is a clinical study titled "Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects". This is an open-label, single-dose, absorption, metabolism, excretion, and mass balance study following a single IV infusion of \[14C\]-VVZ-149 in healthy adult male subjects. Whole blood, plasma, urine, and fecal samples will be analyzed for at least 72 hours following the start of infusion to meas...
What is the current status of trial NCT04415645?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2020-02-24. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT04415645?
The interventions under investigation include: [14C]-VVZ-149 (DRUG).
Who is sponsoring clinical trial NCT04415645?
This trial is sponsored by Vivozon, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04415645's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI